Advertisement

International Journal of Hematology

, Volume 107, Issue 6, pp 717–719 | Cite as

Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration

  • Hiroki Hosoi
  • Toshiki Mushino
  • Akinori Nishikawa
  • Hisako Hashimoto
  • Shogo Murata
  • Kazuo Hatanaka
  • Shinobu Tamura
  • Nobuyuki Hanaoka
  • Norio Shimizu
  • Takashi Sonoki
Letter to the Editor
We read with great interest the two articles by Tsubokura et al. and Ishitsuka et al. on allogeneic hematopoietic stem cell transplantation (allo-HSCT) for adult T-cell leukemia/lymphoma (ATLL) [ 1, 2]. Regimens containing mogamulizumab (Mog), an anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, are expected to achieve good disease control before allo-HSCT and may result in low relapse rate after allo-HSCT. However, there is a concern that the use of Mog before allo-HSCT may cause severe acute graft-versus-host disease (aGVHD), as Mog eradicates normal CCR4-positive cells, including regulatory T cells (Tregs). Fuji et al. reported that Mog administration is associated with significantly increased risk of severe aGVHD due to such reduction in Tregs [ 3]. At present, there is no consensus on how to use Mog before allo-HSCT in Japan. Recently, Tsubokura et al. reported that monitoring of Tregs was useful for avoiding severe aGVHD [ 1]. Ishitsuka et al. demonstrated that the interval...

Notes

Compliance with ethical standards

Conflict of interest

None of the authors have any financial conflicts of interest related with this work.

References

  1. 1.
    Tsubokura Y, Satake A, Hotta M, Yoshimura H, Fujita S, Azuma Y, et al. Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases. Int J Hematol. 2016;104:744–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Ishitsuka K, Yurimoto S, Kawamura K, Tsuji Y, Iwabuchi M, Takahashi T, et al. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan interim results of postmarketing all-case surveillance. Int J Hematol. 2017:106:522–532.CrossRefPubMedGoogle Scholar
  3. 3.
    Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. J Clin Oncol. 2016;34:3426–33.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Hiroki Hosoi
    • 1
  • Toshiki Mushino
    • 1
  • Akinori Nishikawa
    • 1
  • Hisako Hashimoto
    • 2
  • Shogo Murata
    • 1
  • Kazuo Hatanaka
    • 1
    • 4
  • Shinobu Tamura
    • 1
  • Nobuyuki Hanaoka
    • 1
    • 5
  • Norio Shimizu
    • 3
  • Takashi Sonoki
    • 1
  1. 1.Hematology/OncologyWakayama Medical UniversityWakayamaJapan
  2. 2.Department of Cell TherapyInstitute of Biomedical Research and InnovationKobeJapan
  3. 3.Division of Advanced Biomedical Engineering Research, Center for Stem Cell and Regenerative MedicineInstitute of Research, Tokyo Medical and Dental UniversityTokyoJapan
  4. 4.Department of HematologyOsaka Red Cross HospitalOsakaJapan
  5. 5.Department of General MedicineNational Hospital Organization, Kumamoto Minami HospitalKumamotoJapan

Personalised recommendations